Onassis Holdings Corp. announced its entry into the rejuvenation therapy market with a epigenetic programming technology. Through an exclusive perpetual license agreement with a leading Israeli university, Onassis Holdings will have the right to develop, manufacture, market, distribute, and sell products utilizing this cutting-edge technology worldwide.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0395 USD | +27.42% |
|
0.00% | +10.34% |
2023 | Onassis Holdings Corp. announced that it expects to receive $75 million in funding | CI |
2023 | Onassis Holdings Enters the Rejuvenation Therapy Race with Innovative Epigenetic Programming | CI |
1st Jan change | Capi. | |
---|---|---|
+10.34% | 5.05M | |
+29.76% | 5.68B | |
-32.34% | 3.59B | |
-2.23% | 3.12B | |
-25.26% | 2.62B | |
-10.88% | 2.3B | |
+40.09% | 1.88B | |
+40.90% | 1.45B | |
-15.16% | 1.39B | |
+42.86% | 1.37B |
- Stock Market
- Equities
- ONSS Stock
- News Onassis Holdings Corp.
- Onassis Holdings Enters the Rejuvenation Therapy Race with Innovative Epigenetic Programming